Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1664-1687

  Singh Franco, Devada ^a   Ghin, Hoytin Lee ^b   Robles, Gisela I ^a   Borja Hart, Nancy ^a   Perez, Alexandra ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

allergic rhinitis; antihistamine; chronic idiopathic urticaria; levocetirizine; pharmacoeconomic; pharmacokinetics; quality of life

Indexed keywords

ADENOSINE PHOSPHATE; ANTIHISTAMINIC AGENT; CETIRIZINE; CROMOGLYCATE DISODIUM; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; FEXOFENADINE; FLUTICASONE; IMMUNOGLOBULIN E; INTERLEUKIN 4; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; MONTELUKAST; PLACEBO; PREDNISOLONE;

ABNORMAL BEHAVIOR; ADULT; ALLERGIC RHINITIS; ASTHENIA; ATOPIC DERMATITIS; CHILD; CHRONIC URTICARIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRIVING ABILITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; EVENING DOSAGE; FATIGUE; FEBRILE CONVULSION; FEVER; FOOD DRUG INTERACTION; GASTROENTERITIS; HAY FEVER; HEADACHE; HUMAN; IDIOPATHIC DISEASE; INFLUENZA; INSOMNIA; IRRITABILITY; LIPID DIET; LOW DRUG DOSE; NASAL PRURITUS; NONHUMAN; NOSE CONGESTION; NOSE OBSTRUCTION; OCULAR PRURITUS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PERENNIAL RHINITIS; PHARYNGITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SNEEZING; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; WHEEZING;

ADULT; CETIRIZINE; CHILD; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

EID: 72149097620     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.08.015     Document Type: Review

References (62)

1. Wallace D.V., Dykewicz M.S., Bernstein D.I., et al., the Joint Task Force on Practice, American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: An updated practice parameter [published correction appears in J Allergy Clin Immunol. 2008;122:1237]. J Allergy Clin Immunol. 122 Suppl (2008) S1-S84
2. Grattan C.E., Sabroe R.A., and Greaves M.W. Chronic urticaria. J Am Acad Dermatol. 46 (2002) 645-657
3. Brodell L.A., and Beck L.A. Differential diagnosis of chronic urticaria. Ann Allergy Asthma Immunol. 100 (2008) 181-188
4. Ozkan M., Oflaz S.B., Kocaman N., et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 99 (2007) 29-33
5. Delong L.K., Culler S.D., Saini S.S., et al. Annual direct and indirect health care costs of chronic idiopathic urticaria: A cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 144 (2008) 35-39
6. Morgan M., and Khan D.A. Therapeutic alternatives for chronic urticaria: An evidence-based review, Part 1. Ann Allergy Asthma Immunol. 100 (2008) 403-411
7. Morgan M., and Khan D.A. Therapeutic alternatives for chronic urticaria: An evidence-based review, Part 2. Ann Allergy Asthma Immunol. 100 (2008) 517-526
8. Xyzal [package insert] (2008), UCB Pharma, Smyrna, Ga
9. May J.R., and Smith P.H. Allergic rhinitis. In: DiPiro J.T., Talbert R.L., Yee G.C., et al. (Eds). Pharmacotherapy: A Pathophysiologic Approach. 7th ed. (2008), McGraw-Hill, New York, NY 1565-1575
10. Babe K.S., and Serafin W.E. Histamine, bradykinin, and their antagonists. In: Hardman J.G., Limbird L.E., Molinoff P.B., and Ruddon R.W. (Eds). Goodman & Oilman's The Pharmacological Basis of Therapeutics. 9th ed. (1996), McGraw-Hill, New York, NY 581-600
11. Al Suleimani Y.M., and Walker M.J. Allergic rhinitis and its pharmacology. Pharmacol Ther. 114 (2007) 233-260
12. Haberal I., and Corey J.P. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg. 129 (2003) 274-279
13. Wang D., Clement P., Smitz J., et al. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol. 106 (1995) 278-285
14. Bousquet J., Neukirch F., Bousquet P.J., et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 117 (2006) 158-162
15. Bordell L.A., Beck L.A., and Saini S.S. Pathophysiology of chronic urticaria. Ann Allergy Asthma Immunol. 100 (2008) 291-297
16. Sabroe R.A., Seed P.T., Francis D.M., et al. Chronic idopathic urticaria: Comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoanti-bodies. J Am Acad Dermatol. 40 (1999) 443-450
17. Kulthanan K., Jiamton S., Thumpimukvatana N., and Pinkaew S. Chronic idiopathic urticaria: Prevalence and clinical course. J Dermatol. 34 (2007) 294-301
18. Raap U., Gieler U., and Schmid-Ott G. Urticaria. Dermatol Psychosom. 5 (2004) 203-205
19. Fromer L. Treatment options for the relief of chronic idio-pathic urticaria symptoms. South MedJ. 101 (2008) 186-192
20. Gillard M., Van der Perren C., Moguilevsky N., et al. Major role for the carboxylic function of cetirizine and levocetirizine in their binding characteristics to human H1-histamine-receptors. Inflamm Res. 51 Suppl 1 (2002) S79-S80
21. Gupta A., Gillard M., Christophe B., et al. Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating anti-histamine: A time-course study in the guinea pig. Br J Pharmacol. 151 (2007) 1129-1136
22. Thomson L., Blaylock M.G., Sexton D.W., et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy. 32 (2002) 1187-1192
23. Ciprandi G., Cirillo I., Vizzaccaro A., and Tosca M.A. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: A pilot study. Clin Exp Allergy. 34 (2004) 958-964
24. Strolin Benedetti M., Plisnier M., Kaise J., et al. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol. 57 (2001) 571-582
25. Bree F., Thiault L., Gautiers G., et al. Blood distribution of levocetirizine, a new non-sedating histamine H1-receptor antagonist, in humans. Fundam Clin Pharmacol. 16 (2002) 471-478
26. Simons F.E., and Simons K.J. Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol. 116 (2005) 355-361
27. Cranswick N., Turzàkova J., Fuchs M., and Hulhoven R. Levocetirizine in 1-2 year old children: Pharmacokinetic and pharmacodynamic profile. Int J Clin Pharmacol Ther. 43 (2005) 172-177
28. Simons F.E., and the ETAC Study Group. Population pharmacokinetics of levocetirizine in very young children: The pediatricians' perspective. Pediatr Allergy Immunol. 16 (2005) 97-103
29. Hussein Z., Pitsiu M., Majid O., et al., the ETAC Study Group. Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: The ETAC study. Br J Clin Pharmacol. 59 (2005) 28-37
30. Grant J.A., Riethuisen J., Moulaert B., and DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolas-tine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 88 (2002) 190-197
31. Popov T.A., Dumitrascu D., Bachvarova A., et al. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res 55 (2006) 241-244
32. Karppinen A., Brummer-Korvenkontio H., Petman L., et al. Levocetirizine for treatment of immediate and delayed mosquito bite reactions. Acta Derm Venereol 86 (2006) 329-331
33. Lee D.K., Gray R.D., Wilson A.M., et al. Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br J Clin Pharmacol 58 (2004) 34-39
34. Juniper E.F., and Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21 (1991) 77-83
35. Juniper E.F., Thompson A.K., Ferrie P.J., and Roberts J.N. Development and validation of the mini Rhinoconjuncti-vitis Quality of Life Questionnaire. Clin Exp Allergy 30 (2000) 132-140
36. Juniper E.F., Howland W.C., Roberts N.B., et al. Measuring quality of life in children with rhinoconjunctivitis. J Alleg Clin Immunol 101 (1998) 163-170
37. Baiardini I., Pasquali M., Giardini A., et al. Rhinasthma: A new specific QoL questionnaire for patients with rhinitis and asthma. Allergy 58 (2003) 289-294
38. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994) 210-216
39. Potter P.C., and the Study Group. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy 58 (2003) 893-899
40. Potter P.C., and the Paediatric Levocetirizine Study Group. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: A double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol 95 (2005) 175-180
41. Bachert C., Bousquet J., Canonica G.W., et al., the XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 114 (2004) 838-844
42. Canonica G.W., Bousquet J., Van Hammée G., et al., the XPERT Study Group. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med 100 (2006) 1706-1715
43. Klimek L., Bachert C., Canonica G.W., et al., the XPERT Study Group. Long-term treatment of persistent allergic rhinitis with levocetirizine: Improvements in activity and sleep items of the Rhinoconjuncti-vitis Quality of Life Questionnaire (RQLQ). Allergy Clin Immunol Int-J World Allergy Org 19 (2007) 4-10
44. Ciprandi G., Cirillo I., Vizzaccaro A., et al. Desloratadine and levocetiri-zine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: A pilot study. Int Immunopharmacol 5 (2005) 1800-1808
45. Ciebiada M., Górska-Ciebiada M., DuBuske L.M., and Górski P. Montelu- kast with desloratadine or levoceti-rizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 97 (2006) 664-671
46. Ciebiada M., Ciebiada M.G., Kmiecik T., et al. Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetiri-zine or desloratadine. J Investig Allergol Clin Immunol 18 (2008) 343-349
47. Canonica W., Fumagalli F., Guerra L., et al., the Global Allergy and Asthma European Network. Levo-cetirizine in persistent allergic rhinitis: Continuous or on-demand use? A pilot study. Curr Med Res Opin 24 (2008) 2829-2839
48. de Blic J., Wahn U., Billard E., et al. Levocetirizine in children: Evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 16 (2005) 267-275
49. Jorissen M., Bertrand B., Stiels B., and Vandenbulcke K. Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. B-ENT 2 (2006) 55-62
50. Barnes M.L., Ward J.H., Fardon T.C., and Lipworth B.J. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy 36 (2006) 676-684
51. Nettis E., Colanardi M.C., Barra L., et al. Levocetirizine in the treatment of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Br J Dermatol 154 (2006) 533-538
52. Kapp A., and Pichler W.J. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 45 (2006) 469-474
53. Potter P.C., Kapp A., Maurer M., et al. Comparison of the efficacy of levo-cetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy 64 (2009) 596-604
54. Garg G., and Thami G.P. Comparative efficacy of cetirizine and levocetiri-zine in chronic idiopathic urticaria. J Dermatolog Treat 18 (2007) 23-24
55. Layton D., Wilton L., Boshier A., et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: A prescription-event monitoring study in England. DrugSaf 29 (2006) 897-909
56. Verster J.C., de Weert A.M., Bijtjes S.I., et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: A randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 169 (2003) 84-90
57. Simons F.E., and the Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine in young atopic children: An 18-month study. Pediatr Allergy Immunol 18 (2007) 535-542
58. Hogge J. Rx product listings. In: Fleming T. (Ed). Drug Topics Red Book (2009), Thomson Healthcare, Montvale, NJ
59. Xyzal (levocetirizine dihydrochloride). Help your patients save with the power of experience!. http://www. xyzal.com/HCP/Reimbursement.aspx Accessed May 23, 2008
60. Bousquet J., Demarteau N., Mullol J., et al., the XPERT Study Group. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 60 (2005) 788-794
61. Goodman M.J., Jhaveri M., Saverno K., et al. Cost-effectiveness of second-generation antihistamines and mon-telukast in relieving allergic rhinitis nasal symptoms. Am Health Drug Benefits 1 (2008) 26-34
62. Kapp A., and Demarteau N. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: A pooled analysis of two randomised controlled trials. Clin Drug Investig 26 (2006) 1-11